Please assess the completion status of the following clinical trial:

Trial Title: A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosed with persistent asthma for 3 months or longer.~* Experienced worsened asthma symptoms during physical activity.~* Using an inhaled steroid for the previous 4 weeks or longer (such as Aerobid, Azmacort, Flovent, Pulmicort, QVAR, and Vanceril).~Exclusion criteria:~* Used systemic steroids as either liquids, pills, or injections to treat asthma within the previous 3 months.~* Have only intermittent, seasonal, or exercise-induced asthma, and not persistent asthma.~* Admitted to a hospital within the previous 6 months due to asthma symptoms.~* Any poorly controlled medical conditions that may make study participation unsafe or inappropriate in the opinion of the study physician (such as cystic fibrosis, congenital heart disease, insulin dependent diabetes, glaucoma, drug allergies, etc.)~* The study physician will evaluate other medical criteria.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- FSC 100/50 mcg BID (Type: EXPERIMENTAL): Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
- FP 100 mcg BID (Type: EXPERIMENTAL): Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).